Abstract: This invention relates to a single phase emulsifiable concentrate composition comprising (a) between about 0.05 and about 25 wt. % of a biologically, fungicidally and/or herbicidally active aza compound; (b) between about 2 and about 40 wt. % of a lactam selected from the group of N-methyl pyrrolidone, N-methyl caprolactam, a C8 to C18 alkyl pyrrolidone, a C8 to C18 caprolactam and a mixture thereof; (c) between about 2 and about 20 wt. % of a moisture scavenging agent selected from the group consisting of a liquid molecularly hindered carbodiimide, a molecular sieve or a mixture thereof and (d) between about 10 and about 80 wt. % of a mixture of at least two non-ionic surfactants having an overall hydrophilic/lipophilic balance (HLB) above 7. The invention also relates to the stable oil-in-water (o/w) miniemulsions prepared from the above by dilution to between about 40 and about 99.99 wt. % water for a “pour on”, dip or spray solution useful in the treatment of animals or plants.

Abstract: A tablet for the transmucosal administration of nicotine. The nicotine is in one or more layers upon a non-nicotine containing matrix. The nicotine layers rapidly dissolve in the mouth. The nicotine is then rapidly absorbed by the intra-oral mucosal surfaces. The short, rapid pulse of nicotine is similar to that given by cigarette smoking. The nicotine may be provided in a plurality of layers separated by one or more layers that are essentially free of nicotine to support the nicotine layers.

Abstract: Novel, stable formulations of bupropion hydrochloride are provided which will maintain at least 80% of initial bupropion hydrochloride potency after one year. Methods of inhibiting degradation of bupropion hydrochloride and methods of preparing stable formulations of bupropion hydrochloride are also provided.

Abstract: The present invention provides a novel formulation in a composition comprising FeCl3 and a dialkyl diallyl ammonium polymer where the FeCl3 has been diluted with water prior to being mixed with the polymer providing a stable composition.

Abstract: A stabilized, injectable pharmaceutical composition for human administration comprises (a) an antineoplastic compound,(b) a solubilizing/dispersing agent, and (c) a stabilizing amount of an anti-oxidant.

Abstract: Disclosed are pharmaceutical composition of a sterile, injectable physiologically acceptable solution containing nitric oxide (NO), processes for preparing the compositions and a process for detecting physiologically present NO. With these NO solutions, NO in high doses can trigger locally in vessels, e.g. coronary vessels, specific local biological effects such as relaxation of the smooth vascular musculature, inhibition of thee adhesion of thrombocytes, etc., without producing systemic side-effects, such as for example, a critical drop in blood pressure, in spite of the high does. The detection process enables the presence of an endothelial dysfunction to be established from the whole blood of humans and other mammals.

Abstract: The present application relates to an extruded cosmetic composition, provided in the form of a soft paste, comprising, in a fatty phase, at least one compound having a high melting temperature.The invention also relates to a process for preparing the composition by extrusion.

Abstract: Novel, stable formulations of bupropion hydrochloride are provided which will maintain at least 80% of initial bupropion hydrochloride potency after one year. Methods of inhibiting degradation of bupropion hydrochloride are also provided.

Abstract: The invention relates to the use of a chemical agent of organic origin for reducing or eliminating changes in waistline or for reducing or eliminating constipation due to the taking of other agents. A preferred agent is a polyvinylpyrrolidone or povidone. By virtue of the invention, changes in waistline are reduced or eliminated during the day, as well as constipation which can be generated by the taking of other agents such as clays.

Abstract: Cosmetic/pharmaceutical/hygienic compositions (e.g., lipcolors) are formulated as homogeneous and stable, supple dough extrudates, said supple dough extrudates having at least one thermally-unmodified but normally heat-sensitive compound (for example a volatile compound and/or a compound having a low flash point) and at least one elevated melting temperature T compound (for example a wax) homogeneously distributed therethrough.

Abstract: A compact solid gel is described containing water, that consists of water in a concentration ranging from 15% to 90%, thermoreversible polysaccharides in a concentration ranging from 0.3% to 4%, humectant compounds in a concentration ranging from 4% to 40%, and powder phase in a concentration ranging from 2% to 35%.

Abstract: A method of treating headaches that involves generating chilled air, conveying the air to the patient, and inhaling the chilled air until relief is obtained.Apparatus for generating chilled air for the treatment of headaches that includes a heat exchanger located in an insulated housing, a fan for moving air over the heat exchanger, a conduit connected to the housing for conveying the chilled air to a face mask for inhalation by the patient.

Abstract: The present application relates to an extruded cosmetic composition, provided in the form of a soft paste, comprising, in a fatty phase, at least one compound having a high melting temperature.The invention also relates to a process for preparing the composition by extrusion.

Abstract: This invention provides a method for controlling soilborne fungal disease in cultivated field plants such as a peanut crop. Field crop soil is treated with a free-flowing granular fungicide composition which can be applied by aerial means with minimal settling on plant foliage. The granular fungicide composition comprises ammonium bicarbonate and a solid surfactant ingredient, and is effective against soilborne fungi such as a Sclerotinia, Rhizoctonia, Pythium, Fusarium, Phytophthora or Verticillium species.

Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

Abstract: A method to prevent the degradation of water soluble film placed in contact with halogenated hydantoin or chlorinated cyanuric acid and an apparatus for disinfecting water systems. Halogenated 5,5-dialkyl hydantoin or chlorinated cyanuric acid is combined with a stabilizing agent to prevent the halogenated hydantoin or chlorinated cyanuric acid from discoloring or degrading a polymeric film which it may contact. The oxidizing agent includes alkaline hydroxide, alkaline carbonates, alkaline bicarbonates, alkaline phosphates, alkaline silicates, and alkaline borates. Polymeric films for which this is suitable include 2-hydroxy propyl cellulose and poly(vinyl alcohol).

Abstract: Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.

Abstract: A bioresorbable string of implantable beads in which the beads consist essentially of calcium sulfate and a quantity of a drug suitable for treating tissue disorders, and in which both the beads and the line that joins the beads together are bioresorbable.

Abstract: The disclosed invention provides agricultural chemical compositions containing active carbon-treated thifluzamide as an effective ingredient. Such compositions provide increased release of thifluzamide into water.

Abstract: A method has been discovered for repelling ants by treating objects or areas with effective amounts of compositions that include (a) one or more C.sub.6 to C.sub.8 carboxylic acids; (b) one or more C.sub.6 to C.sub.14 alcohols; (c) one or more esters which are reaction products of (a) and (b) or an ester which is a reaction product of the repellents and other carboxylic acids or alcohols; (d) one or more C.sub.6 to C.sub.11 carboxylic acid esters; (e) one or more C.sub.6 to C.sub.14 ketones; or (f) mixtures thereof.

Abstract: A method is provided for increasing and maintaining the quantity and activity of immune leukocyte effector cells in preparation for lymphokine and cytokine administration before and during treatment for disease pathogens. The method simultaneously up-regulates the expression of high affinity IL-2 receptors on the above mentioned cells, making them receptive to subsequent IL-2 administration, which activates and directs these cells to mediate cytotoxic activity against disease pathogens. The method may also be employed in conjunction with the administration of other lymphokines, cytokines, biological response modifiers and pharmacological compounds whose activity would benefit from an increase in effector cells. The preferred method of administration is by inhalation of a zinc oxide fume or particulate from 15 to 900 mg ZnO/m.sup.3 for one or more exposures per day, one hour or less per exposure.

Abstract: A safe, stabilized lyophilized preparation comprising parathyroid hormone (PTH) as an active ingredient and effective amounts of sugar and sodium chloride to provide a stable preparation of parathyroid hormone.

Abstract: The present invention provides a physiologically active substance which inhibits plasma kallikrein production, improves peripheral blood flow, and exhibits analgesic, antiinflammatory and antiallergic action. The physiologically active substance of the present invention is prepared by activating various animals or animal tissues by means of inoculation with virus or tumor cells which act as a stressor, and then extracting the effective factor from the activated tissues. The substance exhibits a pharmacological action of inhibiting activity for production of plasma kallikrein and recovering and normalizing abnormal functions which are associated with the diseased state. The physiologically active substance and pharmaceutical compositions of the present invention exhibit excellent regulating activity for biofunctions. They provide recovery and normalization of abnormal functions in living organisms in various diseased states.

Abstract: New and improved compositions comprising particulates and an effective amount of manganese chloride to reduce significantly the wetting time and/or the dispersion time of said particulates relative to said time(s) in the absence of said salt(s) have been discovered. Methods for reducing the wetting time of particulates in liquid have also been discovered.

Abstract: This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.

Abstract: New and improved compositions comprising particulates and an effective amount of one or more effective salt(s) to reduce significantly the wetting time and/or the dispersion time of said particulates relative to said time(s) in the absence of said salt(s) have been discovered. Methods for reducing the wetting time of particulates in liquid have also been discovered.

Abstract: A slow-release pharmaceutical composition containing a bile acid as active ingredient and comprising at least one bioadhesive substance and at least one high specific gravity substance, an aliquot thereof being enteric coated and the remainder being non-enteric coated.

Abstract: The present invention relates to aqueous depot formulations of hirudin, particularly desulphatohirudin, which are very stable. These formulations contain water, hirudin, and calcium, magnesium, or zinc ions in the form of water insoluble salts, the salts being in a concentration of from 100 mM to 600 mM.

Abstract: The present invention provides a fungicide composition which contains ingredients which are biocompatible for purposes of agricultural applications, and which are harmless to animals and humans. An invention fungicide composition in the form of a dry blend formulation remains non-caking and free-flowing under storage conditions. Illustrative of an invention fungicide composition is a formulation which has a content of sodium bicarbonate, potassium bicarbonate, xanthan gum, dialkylsulfosuccinate salt and alkyl sulfate salt surfactants, and magnesium silicate anti-caking ingredient. The xanthan gum and surfactants function as an effective spreader-sticker and film-forming medium when the composition is diluted with water for agricultural applications.

Abstract: This invention provides a co-micronized bicarbonate salt composition which is a blend of ingredients having a particle size between about 0.01-1.0 micron. The composition is produced by mill co-micronization of a crystalline bicarbonate ingredient and a crystalline inorganic compound ingredient having a Mohs hardness value between about 3-7. A co-micronized blend such as sodium bicarbonate and zinc oxide is free-flowing and essentially free of agglomerated particles.

Abstract: A composition comprising (a) a metal salt or complex with an organic compound of the general formula ##STR1## and (b) an oxy-phosphorus compound where W may be --SH or an optionally substituted hydrocarbyl group, Q is --OH, hydrogen or optionally substituted hydrocarbyl and Z is hydrogen or optionally substituted hydrocarbyl and Q and Z or Z and W may complete a ring. The compounds are typically metal complexes of thiohydroxamic acids or dithiocarbamates. The metal is typically zinc. The compositions exhibit improved aqueous solubility compared with the metal complexes alone, and can be used as industrial biocides, especially fungicides and particularly in paint films and latices.

Abstract: This invention provides a co-micronized bicarbonate salt composition which is a blend of ingredients having a particle size between about 0.01-1.0 micron. The composition is produced by mill co-micronization of a crystalline bicarbonate ingredient and a crystalline inorganic compound ingredient having a Mohs hardness value between about 3-7. A co-micronized blend such as sodium bicarbonate and zinc oxide is free-flowing and essentially free of agglomerated particles.

Abstract: The present invention provides a fungicide composition which contains ingredients which are biocompatible for purposes of agricultural applications, and which are harmless to animals and humans. An invention fungicide composition in the form of a dry blend formulation remains non-caking and free-flowing under storage conditions. Illustrative of an invention fungicide composition is a formulation which has a content of sodium bicarbonate, potassium bicarbonate, xanthan gum, dialkylsulfosuccinate salt and alkyl sulfate salt surfactants, and magnesium silicate anti-caking ingredient. The xanthan gum and surfactants function as an effective spreader-sticker and film-forming medium when the composition is diluted with water for agricultural applications.

Abstract: ACTH polymeric controlled release systems are described wherein the ACTH retains good biological activity and is released over an extended period of time following administration by injection. In the preferred embodiment, the ACTH polymeric microspheres are made using very cold temperatures to freeze the polymer-ACTH mixtures into polymeric microspheres with very high retention of biological activity and material. Sustained release of biologically active ACTH is achieved when the microspheres are tested in vitro, extending over a period of greater than one day to several months. Altered release can be achieved by inclusion of degradation modifiers, pore forming agents, and stabilizers of the ACTH.

Abstract: Pharmaceutically acceptable solutions of acidic, basic or amphoteric pharmaceutical agents are disclosed. These solutions are suitable for encapsulation in gelatin capsules for subsequent oral administration and include the pharmaceutical agent, an ion species and a solvent system.

Abstract: The invention relates to a controlled-release composition for a biologically active material, wherein said active material has been dissolved or dispersed in an L2-phase comprising(a) at least one monoglyceride of an unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such a monoglyceride,(b) at least one triglyceride of at least one unsaturated fatty acid having 16-22 carbon atoms or a vegetable or animal oil containing such triglycerides and(c) at least one polar liquid selected from the group consisting of water, glycerol, ethylene glycol and propylene glycol. Such L2 phases are known per se but are novel in this context.The composition is prepared by forming the L2 phase and adding the biologically active material before, during or after the formation of the L2-phase. For sensitive substances such as proteins a mixture of the mono- and triglycerides is added dropwisely to a solution of said substance in the polar liquid.

Abstract: This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.

Abstract: In the combating of agricultural and horticultural pests by applying to a locus from which it is desired to exclude such pests a normally liquid active compound and a normally solid active compound, the improvement which comprises applying such active compound in the form of granules comprisinga) carrier granules having a non-absorptive surface,b) at least one liquid active compound and at least one solid active compound,c) at least one adhesive based on polyurethane as a binder, optionally mixed with a further adhesive selected from the group consisting of polyvinyl acetate, polyvinylpyrrolidine, polyvinyl alcohol, vinyl acetate/di-n-butyl maleate copolymers, acrylic acid ester, vinyl acetate/ethylene, vinyl acetate/ethylene/vinyl chloride, vinyl acetate/acrylic acid ester, vinyl acetate/vinyl ester and styrene/acrylic acid ester, andd) optionally an additive.

Abstract: Cosmetic deodorants, characterized by an effective content of lantibiotics, it being possible for the lantibiotics to be present both singly and in a mixture.

Abstract: A continuous process for preparing a paste or cream like material which comprises the steps of means for forming under non vacuum conditions at a temperature of 90.degree. F. to 120.degree. F. a first low viscosity homogenous slurry of at least one non aqueous solvent and a gelling or bodying agent; means for forming a second low viscosity homogenous slurry under non vacuum conditions at a temperature of 90.degree. F. to 130.degree. F., means for forming a low viscosity mixture of said first low viscosity slurry and said second low viscosity slurry by a high shear mixing under non vacuum conditions at a temperature of 90.degree. F. to 130.degree. F. for 0.1 to 5 seconds; means for transforming under non vacuum and non mixing conditions at a temperature of 65.degree. F. to 120.degree. F., said low viscosity mixture into a non Newtonian mixture; and means for deaerating said non Newtonian mixture under vacuum conditions for a period of less than 3 seconds to form said paste or cream like material.

Abstract: A composition containing a high concentration of a biologically active drug and a method for the use thereof to reduce vial breakage in a lyophilization process are disclosed.

Abstract: Disclosed are drug delivery systems based on a polymeric component which is soluble or insoluble (cross-linked) hyaluronan or hyaluronan copolymerized with another hydrophilic polymer or hylan and one or more substances having biological or pharmacological activity and methods of preparing same.

Abstract: New blood substitutes are described having osmolarities greater than normal blood. The new blood substitues typically comprise a physiologically acceptable fluid electrolyte solution, a physiologically acceptable agent capable of increasing the osmolarity of the blood substitute to a value greater than normal blood, an oxygen carrying substance, and a sufficient amount of water to achieve the desired osmolarity. The blood substitutes of the present invention have osmolarities in the range of 500-800 milliosmoles per liter.

Abstract: The instant invention relates to a method for converting phosphorus containing polymers from a two dimensional, layered structure into a three dimensional structure by crosslinking such layers. The method and the resulting crosslinked polymers may be used to encapsulate active materials such as catalysts, pesticides, etc. by intercalating such active materials between the layers prior to crosslinking. Thus, the egress of said active materials into the environment during use may be hindered or prevented. The crosslinking polymers, themselves, may also be used as catalysts or as selective sorbents.

Abstract: There is provided an orally ingestible liquid composition for suspending therein an orally administrable pharmaceutically active composition releasable over an extended period of time comprises triglyceride of a medium chain length alkanoic acid or distilled acetylated monoglycerides, a liquid, high HLB polyglyceryl ester, and colloidal silicon dioxide together with a material soluble or dispersible therein and capable of being insolubilized by a pharmaceutically acceptable polyvalent cation and a solid pharmaceutically acceptable salt containing the cation required therefore. Sustained release compositions based thereon containing pharmaceutically active agents are also disclosed.

Abstract: Controlled release compositions are manufactured by subjecting cellulosic pulp rejects to a dewatering operation to remove approximately 25% of the water; flash-drying the obtained partially dewatered rejects, causing the rejects to expand and become porous; adding an additive material to impregnate the expanded and porous cellulosic material, and drying. The cellulosic material holds or retains the additive for delayed release. The compositions have good stability and structural integrity.

Abstract: A stable soothing hydroalcoholic skin preparation for shaving purposes employing alcohol as a carrier or solvent for the remainder of the composition comprising a combined allantoin-boric acid hydrolyzed solution in combination with glycerine, menthol, ethyl alchohol and fragrance.

Abstract: Mercaptan odors in a thiophosphate compound or formulation are suppressed by treatment of the compound during preparation of the formulation with treatment agents selected from iodine, and alkali and alkaline earth metal hydroxides, hypochlorites and iodates. Depending on the particular agent and method of treatment used, the agent and any reaction products resulting from the treatment may be either removed from the thiophosphate or retained with it in the final formulation. Formulations of particular interest are granular formulations for field application.

Abstract: An improved composition and process for preparing the composition is provided for strengthening and hardening human fingernails and toenails. A base composition comprising lanolin, unsalted butter, beeswax, rosin, copper acetate, turpentine is mixed with titanium dioxide, mineral oil and fragrance.

Abstract: The present invention discloses a method and aqueous composition for hardening and strengthening the keratinized appendages of mammals, and the nail keratin of humans, in particular. The aqueous keratin hardening and strengthening composition includes an effective amount of fluoride ion. The topical application of the fluoride ion is effected from an aqueous cosmetic vehicle capable of maintaining moist contact with the keratin for a sufficient period of time in the method practiced. Auxiliary keratin-strengthening agents are also disclosed.